🔎 Trials Near Me

Beranda › Leukemia Limfositik Kronis › Texas › Houston

Uji klinis Leukemia Limfositik Kronis di Houston, TX

17 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Menerima pesertaFase 1
  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
Hingga usia 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT01853631

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • UT MD Anderson Cancer Center, Houston
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Menerima pesertaFase 1/2
  • Research Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Menerima pesertaFase 1/2
  • Md Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Menerima pesertaFase 3
  • Md Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06973187

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Menerima pesertaFase 3
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Menerima pesertaFase 2
  • M D Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04169737

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Menerima pesertaFase 1/2
  • Research Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06564038

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Menerima pesertaFase 1/2
  • MD Anderson, Houston
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT04588922

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Menerima pesertaFase 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Menerima pesertaFase 2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT06967610

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT04830137

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Menerima pesertaFase 4
  • University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Menerima pesertaFase 4
  • University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876649

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Menerima pesertaFase 1
  • Oncology Consultants, Houston
  • University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363

Uji klinis Leukemia Limfositik Kronis di kota lain

Studi lain di Houston

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.